Cargando…
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma
BACKGROUND: Cisplatin and other anticancer drugs are important in the treatment of head and neck squamous cell carcinoma; however, some tumours develop drug resistance. If chemoresistance could be determined before treatment, unnecessary drug administration would be avoided. Here, we investigated ch...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134508/ https://www.ncbi.nlm.nih.gov/pubmed/25032734 http://dx.doi.org/10.1038/bjc.2014.395 |
_version_ | 1782330881929641984 |
---|---|
author | Nishimura, K Tsuchiya, Y Okamoto, H Ijichi, K Gosho, M Fukayama, M Yoshikawa, K Ueda, H Bradford, C R Carey, T E Ogawa, T |
author_facet | Nishimura, K Tsuchiya, Y Okamoto, H Ijichi, K Gosho, M Fukayama, M Yoshikawa, K Ueda, H Bradford, C R Carey, T E Ogawa, T |
author_sort | Nishimura, K |
collection | PubMed |
description | BACKGROUND: Cisplatin and other anticancer drugs are important in the treatment of head and neck squamous cell carcinoma; however, some tumours develop drug resistance. If chemoresistance could be determined before treatment, unnecessary drug administration would be avoided. Here, we investigated chemoresistance factors by comprehensive analyses at the protein level. METHODS: Four human carcinoma cell lines were used: cisplatin-sensitive UM-SCC-23, UM-SCC-23-CDDPR with acquired cisplatin resistance, naturally cisplatin-resistant UM-SCC-81B, and UM-SCC-23/WR with acquired 5-fluorouracil resistance. Extracted proteins were labelled with iTRAQ and analysed by tandem mass spectrometry to identify resistance. Protein expression was confirmed by western blotting and functional analysis was carried out using siRNA. RESULTS: Thirteen multiple-drug resistance proteins were identified, as well as seven proteins with specific resistance to cisplatin, including α-enolase. Differential expression of these proteins in cisplatin-resistant and -sensitive cell lines was confirmed by western blotting. Functional analysis for α-enolase by siRNA showed that cisplatin sensitivity significantly was increased in UM-SCC-81B and slightly in UM-SCC-23-CDDPR but not in UM-SCC-23/WR cells. CONCLUSIONS: We identified proteins thought to mediate anticancer drug resistance using recent proteome technology and identified α-enolase as a true cisplatin chemoresistance factor. Such proteins could be used as biomarkers for anticancer agent resistance and as targets of cancer therapy. |
format | Online Article Text |
id | pubmed-4134508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-41345082015-08-12 Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma Nishimura, K Tsuchiya, Y Okamoto, H Ijichi, K Gosho, M Fukayama, M Yoshikawa, K Ueda, H Bradford, C R Carey, T E Ogawa, T Br J Cancer Molecular Diagnostics BACKGROUND: Cisplatin and other anticancer drugs are important in the treatment of head and neck squamous cell carcinoma; however, some tumours develop drug resistance. If chemoresistance could be determined before treatment, unnecessary drug administration would be avoided. Here, we investigated chemoresistance factors by comprehensive analyses at the protein level. METHODS: Four human carcinoma cell lines were used: cisplatin-sensitive UM-SCC-23, UM-SCC-23-CDDPR with acquired cisplatin resistance, naturally cisplatin-resistant UM-SCC-81B, and UM-SCC-23/WR with acquired 5-fluorouracil resistance. Extracted proteins were labelled with iTRAQ and analysed by tandem mass spectrometry to identify resistance. Protein expression was confirmed by western blotting and functional analysis was carried out using siRNA. RESULTS: Thirteen multiple-drug resistance proteins were identified, as well as seven proteins with specific resistance to cisplatin, including α-enolase. Differential expression of these proteins in cisplatin-resistant and -sensitive cell lines was confirmed by western blotting. Functional analysis for α-enolase by siRNA showed that cisplatin sensitivity significantly was increased in UM-SCC-81B and slightly in UM-SCC-23-CDDPR but not in UM-SCC-23/WR cells. CONCLUSIONS: We identified proteins thought to mediate anticancer drug resistance using recent proteome technology and identified α-enolase as a true cisplatin chemoresistance factor. Such proteins could be used as biomarkers for anticancer agent resistance and as targets of cancer therapy. Nature Publishing Group 2014-08-12 2014-07-17 /pmc/articles/PMC4134508/ /pubmed/25032734 http://dx.doi.org/10.1038/bjc.2014.395 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics Nishimura, K Tsuchiya, Y Okamoto, H Ijichi, K Gosho, M Fukayama, M Yoshikawa, K Ueda, H Bradford, C R Carey, T E Ogawa, T Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
title | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
title_full | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
title_fullStr | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
title_full_unstemmed | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
title_short | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
title_sort | identification of chemoresistant factors by protein expression analysis with itraq for head and neck carcinoma |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134508/ https://www.ncbi.nlm.nih.gov/pubmed/25032734 http://dx.doi.org/10.1038/bjc.2014.395 |
work_keys_str_mv | AT nishimurak identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT tsuchiyay identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT okamotoh identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT ijichik identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT goshom identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT fukayamam identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT yoshikawak identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT uedah identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT bradfordcr identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT careyte identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma AT ogawat identificationofchemoresistantfactorsbyproteinexpressionanalysiswithitraqforheadandneckcarcinoma |